Stifel Nicolaus维持对Medexus Pharmaceuticals Inc(MDP)的买入评级
Medexus 制药公司被雷蒙德·詹姆斯提升为优于市场表现
Medexus Pharmaceuticals Inc.获利德金融指定为买入
Medexus Pharmaceuticals Inc.的目标股价由Stifel Nicolaus从3.00加幅至3.50加元/股
Stifel Nicolaus仍然给予Medexus Pharmaceuticals Inc (MDP)买入评级
买入评级Medexus Pharmaceuticals Inc:基于FDA批准和战略举措的增长潜力。
Stifel Nicolaus重申对Medexus Pharmaceuticals Inc (MDP)的买入评级。
Stifel Nicolaus将Medexus Pharmaceuticals Inc的目标股价从C$2.35上调至C$2.80/股。
在第三财季表现不佳之后,Medexus Pharmicals继续在Stifel GMP进行投机性买入;目标股价下调至2.85加元
Medexus Pharmicals Inc (MDP) 获得布鲁姆·伯顿的收购
Stifel Nicolaus 维持对美德克萨斯制药公司(MDP)的买入评级
Echelon Wealth Partners维持对Medexus Pharmicals Inc(MDP)的买入评级
Medexus Pharmicals Inc(MDP)获得 Stifel Nicolaus 的收购
Medexus Pharmicals Inc(MDP)获得Echelon Wealth Partners的买入评
Medexus Pharmicals Inc(MDP)获得Echelon Wealth Partners的买入评
Medexus Pharmicals Inc(MDP)获得 Echelon Wealth Partners 的